Supernus Pharmaceuticals to Participate in March Investor Conferences
ROCKVILLE, Md., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that management will participate in the following March investor conferences:
| TD Cowen 46
th
Annual Health Care Conference |
|
| Date: Fireside chat: Place: Webcast Link: |
Monday, March 2, 2026 2:30 p.m. ET Boston Marriott Copley Place, Boston, Mass. |
| Jefferies Biotech on the Beach Summit | |
| Date: Place: |
Tuesday, March 10, 2026 1 Hotel South Beach, Miami Beach, Fla. |
| Barclays 28th Annual Global Healthcare Conference | |
| Date: Fireside chat: Place: Webcast Link: |
Wednesday, March 11, 2026 2:00 p.m. ET Loews Miami Beach, Miami Beach, Fla. |
Investors interested in arranging a meeting with the Company's management during these conferences should contact the respective conference coordinators.
A live audio webcast of the TD Cowen and Barclays Conference presentations can also be accessed on the Events & Presentations section of the Supernus Pharmaceuticals website at www.supernus.com. Archived replays of these webcasts will be available for 60 days on the Company's website following the conference.
About Supernus Pharmaceuticals, Inc.
Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.
Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson's disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, postpartum depression (PPD), epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel product candidates for CNS disorders.
For more information, please visit www.supernus.com.
CONTACTS:
Jack A. Khattar, President and CEO
Timothy C. Dec, Senior Vice President and CFO
Supernus Pharmaceuticals, Inc.
(301) 838-2591
or
INVESTOR CONTACT:
Peter Vozzo
ICR Healthcare
(443) 213-0505
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like

American Rebel Holdings (AREB) Shares Surge Over 37% After Hours - Here's Why


XRP Flashes 3 Bullish Signals — Is a 2024-Style Surge Next?
